NASDAQ:ARDX Ardelyx (ARDX) Stock Price, News & Analysis $5.90 +0.13 (+2.25%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Ardelyx Stock (NASDAQ:ARDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ardelyx alerts:Sign Up Key Stats Today's Range$5.80▼$6.0050-Day Range$5.58▼$6.9352-Week Range$3.43▼$10.13Volume2.28 million shsAverage Volume4.86 million shsMarket Capitalization$1.37 billionP/E RatioN/ADividend YieldN/APrice Target$11.67Consensus RatingBuy Company OverviewArdelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Read More… War on Elon Escalates… (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Ardelyx Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks84th Percentile Overall ScoreARDX MarketRank™: Ardelyx scored higher than 84% of companies evaluated by MarketBeat, and ranked 211th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingArdelyx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageArdelyx has only been the subject of 3 research reports in the past 90 days.Read more about Ardelyx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ardelyx are expected to grow in the coming year, from ($0.25) to ($0.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -21.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -21.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 8.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ardelyx's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.84% of the outstanding shares of Ardelyx have been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Ardelyx has recently decreased by 0.69%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.32 Percentage of Shares Shorted9.84% of the outstanding shares of Ardelyx have been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Ardelyx has recently decreased by 0.69%, indicating that investor sentiment is improving. News and Social Media2.5 / 5News Sentiment0.44 News SentimentArdelyx has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Ardelyx this week, compared to 8 articles on an average week.Search Interest20 people have searched for ARDX on MarketBeat in the last 30 days. This is an increase of 82% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,320,413.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ardelyx is held by insiders.Percentage Held by Institutions58.92% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ardelyx's insider trading history. Receive ARDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter. Email Address ARDX Stock News HeadlinesArdelyx, Inc. (NASDAQ:ARDX) CEO Michael Raab Sells 7,500 SharesOctober 16, 2024 | insidertrades.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) Insider Sells 49,564 Shares of StockOctober 2, 2024 | insidertrades.comMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.October 29, 2024 | Paradigm Press (Ad)Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual MeetingOctober 28 at 6:24 PM | finance.yahoo.comArdelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology's (ACG) Annual MeetingOctober 28 at 4:05 PM | globenewswire.comArdelyx, Inc. (NASDAQ:ARDX) Receives $11.67 Average PT from AnalystsOctober 28 at 3:36 AM | americanbankingnews.comArdelyx announces presentation of Xphozah data at Kidney WeekOctober 25, 2024 | markets.businessinsider.comArdelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney WeekOctober 25, 2024 | markets.businessinsider.comSee More Headlines ARDX Stock Analysis - Frequently Asked Questions How have ARDX shares performed this year? Ardelyx's stock was trading at $6.20 at the beginning of the year. Since then, ARDX stock has decreased by 4.8% and is now trading at $5.90. View the best growth stocks for 2024 here. How were Ardelyx's earnings last quarter? Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.04. Ardelyx's revenue was up 228.3% compared to the same quarter last year. Who are Ardelyx's major shareholders? Top institutional shareholders of Ardelyx include Hennion & Walsh Asset Management Inc. (0.28%), Inspire Investing LLC (0.03%), Values First Advisors Inc. (0.02%) and Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Michael Raab, Susan Rodriguez, Robert Blanks, Laura A Williams, Elizabeth A Grammer, David P Rosenbaum, Justin A Renz, Robert Ora Felsch, Scott D Sandell and Jeffrey W Jacobs. View institutional ownership trends. How do I buy shares of Ardelyx? Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ardelyx investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), e.l.f. Beauty (ELF), General Electric (GE), Builders FirstSource (BLDR) and ServiceNow (NOW). Company Calendar Last Earnings8/01/2024Today10/29/2024Next Earnings (Confirmed)10/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARDX CUSIPN/A CIK1437402 Webwww.ardelyx.com Phone(510) 745-1700Fax510-745-0493Employees267Year Founded2007Price Target and Rating Average Stock Price Target$11.67 High Stock Price Target$15.00 Low Stock Price Target$7.00 Potential Upside/Downside+97.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,070,000.00 Net Margins-31.02% Pretax Margin-30.68% Return on Equity-39.73% Return on Assets-20.47% Debt Debt-to-Equity Ratio0.68 Current Ratio4.21 Quick Ratio3.99 Sales & Book Value Annual Sales$210.00 million Price / Sales6.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book8.19Miscellaneous Outstanding Shares232,700,000Free Float221,538,000Market Cap$1.37 billion OptionableOptionable Beta0.90 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ARDX) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.